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E-mail address: alain.mauviel@curie.fr (A. MauvielHedgehog (HH) and TGF-b signals control various aspects of embryonic development and cancer pro-
gression. While their canonical signal transduction cascades have been well characterized, there is
increasing evidence that these pathways are able to exert overlapping activities that challenge efﬁ-
cient therapeutic targeting. We herein review the current knowledge on HH signaling and summa-
rize the recent ﬁndings on the crosstalks between the HH and TGF-b pathways in cancer.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Canonical Hedgehog signaling: components andmechanistics
The Hedgehog (HH) pathway plays a critical role during
embryogenesis, in particular in directing limb digit and skeletal
polarity, and in the patterned formation of cells within the ventral
portion of the central nervous system [1,2]. In adulthood, the SHH
pathway is involved in the maintenance of tissue homeostasis and
repair after severe injury [3]. This pathway regulates numerous
important cellular responses such as cell proliferation, survival, dif-
ferentiation, self-renewal ability, migration and epithelial to mes-
enchymal transition (EMT) [4]. Disruption of the HH pathway in
the mouse embryo result in congenital anomalies affecting the
central nervous system, axial skeleton limbs and other organs,
which are found in human pathology such as holoprosencephaly
[5,6]. Conversely, aberrant activations of the HH pathway have
been described in a wide variety of human cancers, including basal
cell carcinoma and medulloblastoma [7–9].al Societies. Published by Elsevier
Centre de Recherche, Team
MR3347, University Center,
).1.1. Hedgehog ligands and receptors
In mammals, there are three secreted HH ligands: Sonic HH,
Indian HH and Desert HH. They are cholesterol- and palmitoyl-
modiﬁed proteins expressed by a wide range of cell types, and bind
the 12-transmembrane receptor PATCHED-1 (PTCH-1). The
functional speciﬁcity of HH proteins is governed in part by their
expression patterns and by regulatory mechanisms in a given cell
type [10–12]. For instance, several HH binding and/or sequestrat-
ing proteins such as PTCH-2, CDO, BOC or HIP and GAS1 have been
characterized. These proteins are considered co-receptors that
modulate ligand presentation to PTCH-1, and positively or
negatively inﬂuence cellular responses to HH ligands [13].
The current model for HH signaling is as follows: in the absence
of HH ligand, PTCH-1 localizes to the primary cilium and inhibits
the activity of the 7-transmembrane G-protein coupled receptor-
like SMOOTHENED (SMO). The primary cilium is a microtubule-
based antenna-like structure that emanates from the surface of a
wide variety of cells in mammals [14]. Signals from the primary
cilium are ultimately involved in regulating the cell cycle, cytoskel-
etal organization, intra-ﬂagellar transport and various signaling
pathways such as HH and WNT [15]. In the absence of HH ligand,
only repressor forms of GLI proteins are translocated into the
nucleus (Fig. 1). Binding of HH ligands to PTCH-1 results in itsB.V. Open access under CC BY-NC-ND license.
Fig. 1. Canonical Hedgehog signaling. In the absence of ligand, the HH pathway is maintained inactive by several mechanisms. In the cilium, PTCH-1 blocks signal
transduction by SMO. Phosphorylation of GLI proteins by PKA, GSK3 or CK1 results in their proteasomal processing into transcription repressor forms through the recruitment
of b-TRCP and SPOP. DYRK2 and DYRK1B phosphorylate GLI proteins and promote repressor form processing. GLI proteins are sequestered in the cytoplasm by their
interaction with 14-3-3 and SUFU. RAB23 and ULK3 promote GLI inhibition by SUFU. In the presence of HH, PTCH-1 is excluded from the cilium and SMO, through GaI,
induces nuclear translocation of GLI proteins. HH-transduced signal is modulated positively or negatively by the interaction of PTCH-1 with co-receptors such as CDO, BOC,
HIP1 and GAS1. In the nucleus, GLI proteins act as transcription factors. Phosphorylation by DYRK1A and ULK3 and acetylation by HDACs of GLI proteins increase their
transcriptional activity. At the chromatin level, GLI activity may be inhibited by the recruitment c-SKI/SNON, SNF5 or SAP18/mSIN3-SUFU. (For more details, refer to text and
reviews in [1,4,8,12,14–16])
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and signal transduction leading to activation and nuclear translo-
cation of GLI transcription factors, and subsequent target gene
transactivation.
1.2. Hedgehog effector molecules: GLI transcription factors
GLI proteins belong to the family of Kruppel-like factors, tran-
scription factors with highly conserved C2H2-Zn ﬁnger DNA-bind-
ing domains. There are three mammalian GLI proteins, GLI1, GLI2,
and GLI3, each encoded by distinct genes. In contrast, their Dro-
sophila homolog, Cubitus interruptus (Ci) is unique [4,16]. GLI pro-
teins exhibit distinct regulations, biochemical properties and
target genes. One study based on the overexpression of either
GLI1 or a dominant-active mutant form of GLI2 in keratinocytes
determined both overlapping and distinct transcriptional pro-
grams for these two proteins [17]. For example, while PTCH-1
and TNC are induced by both GLI1 and GLI2, VGLL4 is exclusively
regulated by GLI1 while LITAF is a GLI2-speciﬁc target. Other stud-
ies have identiﬁed OPN (osteopontin) [18] and MUC5A [19] as GLI1
targets, while functional GLI2 binding sites have been character-
ized on BCL2 [20] PTHrP [21] Follistatin [22] and BMP2 [23]
promoters.
The intrinsic molecular nature of GLI proteins largely contrib-
utes to their functional speciﬁcity. Processing of GLI2 and GLI3
N-terminus represents a critical mechanism allowing regulation
of target genes downstream of HH signaling. In the absence of
HH ligands, GLI3 is sequentially phosphorylated by PKA, GSK3
and CK1 on multiple sites in its C-terminal region. This allows
the recruitment of the F-box protein b-TrCP, an E3 ubiquitin ligasethat targets GLI3 to a limited proteolysis by the proteasome to gen-
erate a repressor form [24] that does not utilize HDACs for tran-
scriptional repression [25]. HH signaling inhibits GLI2 and GLI3
processing, thereby elevating full-length GLI2/3 levels [26,27]. As
GLI3 exhibits only a weak transcriptional activity, it is mainly con-
sidered an inhibitor of HH activity while GLI2 serves as the main
transducer of HH gene responses. GLI2 has a composite structure,
comprising an activator domain in its C-terminus and a repression
domain in its N-terminus, ﬂanking a central ﬁve zinc ﬁnger DNA-
binding domain [26]. Cleavage of the latter (GLI2DN) unmasks
the strong transactivating potential of GLI2. GLI2 is thought to be
the primary transcriptional activator downstream of HH signaling
[28]. GLI1 lacks a repressor domain and is also a potent transcrip-
tional activator. It is not processed proteolytically and is directly
regulated by HH signaling [29], contributing to the ampliﬁcation
of HH responses. It is a direct transcriptional target of GLI2 [30]
and is able to rescue some of GLI2 functions [31].
1.3. Suppressor of Fused, master inhibitor of HH signaling
When SMO is inactivated by PTCH-1, GLI2 and GLI3 interact
with the inhibitory protein SUFU (Suppressor of Fused), and re-
main sequestered in the cytoplasm so that only the repressor forms
can be translocated to the nucleus [32]. SUFU is able to regulate GLI
levels by antagonizing the ubiquitin ligase SPOP, which targets GLI
proteins for complete degradation by the proteasome [33,34].
SUFU may also repress GLI-dependent transcription by recruiting
the histone deacetylase complex SAP18–mSin3 at the nuclear level
[35]. Negative regulations of GLI protein such as proteasomal deg-
radation or sequestration by SUFU are relieved in presence of HH
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they can act as transcription factors. Targeted disruption of SUFU
in mice results in a phenotype with Gorlin syndrome features
[36], a skin cancer condition associated with constitutive HH acti-
vation due to LOF mutation of PTCH-1 [37]. Thus, SUFU appears to
be a tumor suppressor and a major negative regulator of HH signal-
ing as it controls the production of GLI activators and repressors
essential for graded HH signaling, such is observed in the develop-
ing embryo. Remarkably, the tumor-suppressor function of SUFU
may also be mediated by its ability to abrogate the WNT/b-catenin
signaling pathway via inhibition of b-catenin nuclear translocation.
Simultaneous deregulation of the WNT and HH pathways, occur-
ring in response to SUFU loss of function, was shown to be critical
for tumor formation in a multistep model of carcinogenesis [38].
Inactivating mutations of the SUFU gene, and loss of SUFU expres-
sion, have been identiﬁed in prostate cancer and medulloblastoma
[9,39]. Noteworthy, despite ciliary localization of most HH path-
way components, SUFU regulates GLI protein levels and activity
in a cilium-independent manner [33].
1.4. Post-transcriptional control of GLI protein function
Maintenance of GLI proteins in an inactive state and regulation
of their transcriptional activity involves multiple, highly con-
trolled, mechanisms. A number of proteins implicated in positive
and negative regulation of HH signaling outcome have been iden-
tiﬁed, such as RAB23, 14-3-3, STK36, ULK3, SPOP and the DYRK
family of proteins (see Fig. 1).
Inhibition of HH signaling by Rab23 was ﬁrst described during
embryogenesis where they have opposing roles in neural pattern-
ing [40]. Rab23 was recently shown to regulate GLI transcriptional
activity via direct interaction with SUFU [41].
Asaoka and co-workers have shown that GLI proteins associate
with the 14-3-3 protein in a PKA dependent manner, and this
interaction reduces their transcriptional activity [42].
STK36, the mammalian homolog of Drosophila Fu (Fused),
antagonizes the repressive action of SUFU on HH signaling [43].
However, contrary to Fu, STK36 has a limited role since its expres-
sion is dispensable for proper mouse embryonic development [44].
The serine/threonine kinase ULK3, which shares sequence similar-
ity with STK36 and Fu, is able to phosphorylate GLI proteins,
promoting their transcriptional activity [45]. However in the
absence of HH, ULK3 interacts with SUFU and promotes GLI2
processing into a repressor form [45].
DYRK proteins are dual-speciﬁcity tyrosine-regulated kinases
that have positive or negative effect on GLI transcriptional activity
depending on the family member. For instance, DYRK2 was
described as a scaffold protein for an E3 ubiquitin ligase complex
and phosphorylates GLI2 promoting its proteasomal degradation
[46,47]. DYRK1B inhibits GLI2 transcriptional activity and pro-
motes GLI3 processing into a repressor form [48]. On the other
hand, DYRK1A phosphorylates GLI1 that induces GLI1 nuclear
localization and increases its transcriptional activity by phosphor-
ylation [49].
SPOP, a substrate-binding adaptor for the cullin3-based ubiqui-
tin E3 ligase, exerts competitive binding with SUFU to the N- and
C-terminal regions of GLI3 or the C-terminal region of GLI2. SPOP
favors the cleavage of full-length GLI proteins into their repressor
forms, thereby allowing SUFU-independent GLI3 repressor
function [34].
The activity of the HH pathway may also be controlled at the
chromatin level, by transcriptional co-activators and co-repressors.
The activator form of GLI3 utilizes CBP as a co-activator of gene
transcription, as in Drosophila, in which Ci uses dCBP [50,51]. c-
SKI and its homolog SNO-N, both known transcriptional co-repres-
sors of the TGF-b/SMAD pathway (see below), have been identiﬁedin a yeast two-hybrid screen as interacting with both GLI2 and
GLI3 [52]. When bound to GLI3, SKI recruits histone deacetylases
(HDACs), thus contributing to GLI3-mediated transcriptional
repression of target genes. The role of HDACs in HH signaling is
however complex, as GLI1 and GLI2 are acetylated proteins, whose
de-acetylation by HDACs promotes their transcriptional activity, a
phenomenon that is further accentuated by a feed-forward
mechanism whereby HH induces HDAC1 expression. E3 ubiquitin
ligase-mediated degradation of HDAC1 suppresses HH signaling
and HH-dependent growth, while GLI1 acetylation enhances cell
proliferation and transformation [53]. Transcriptional activity of
GLI proteins may also be increased when they are SUMOylated
by the SUMO E3 ligase, PIAS1 [54].
Chromatin remodeling may also play a role in controlling HH
signaling outcome, either positively or negatively. For example,
Brg1, an ATP-dependent chromatin remodeling factor, was shown
to facilitate HDAC binding to HH target genes, enhancing
GLI-dependent transcription. Yet, Brg1 may also repress HH signal-
ing by allowing the recruitment of the repressor form of Gli3 to
DNA, independently from its ATPase activity [55]. Another chroma-
tin remodeling factor, SNF5, directly interacts with GLI1 on speciﬁc
GLI-response elements to repress transcription of target genes [56].
Inversely, loss of SNF5 was shown to enhance HH-dependent gene
expression and growth response.
Finally, expression of various actors of HH signaling can be
regulated by miRNAs. For instance, in medulloblastoma, downreg-
ulation of miR-125b, miR-326 targeting SMO and miR-324-5p
targeting GLI1 has been described [57]. Moreover, the miR-17–92
cluster is overexpressed in human medulloblastoma. This up-regu-
lation is controlled by N-Myc, a target of SHH pathway, and in-
duces loss of PTCH-1 expression [58,59]. In non-small cell lung
cancer, PTCH-1 expression may be downregulated by miR-212
[60]. Also, miR-214, which is expressed during early segmentation
stages of somites, is involved in the regulation of HH-regulated
genes by controlling the expression of the negative regulator SUFU
[61].2. Autocrine and paracrine implication of HH in cancer
In human cancer, HH signaling may be constitutive due to ge-
netic pathway activation via either loss-of-function mutations in
PTCH-1 or SUFU [9,36,62], or gain-of-function mutations in SMO
[63]. In addition, a number of cancers exhibit deregulated GLI
expression or up-regulated expression of HH ligands, without iden-
tiﬁed mutations in upstream components of the pathway. Proto-
typic cancers with mutations in HH pathway components are
medulloblastomas, rhabdomyosarcomas and basal cell carcinomas
(BCC) [64]. Loss of function mutations of PTCH-1 have been identi-
ﬁed in Gorlin syndrome, also known as nevoid basal cell carcinoma
syndrome, in which patients present several developmental disor-
ders and a strong predisposition to BCC [64].
High GLI1 gene ampliﬁcation has been reported in glioblastoma
[65]. Also, several studies have reported that tumor cells in pancre-
atic, lung, esophageal, gastric and prostate cancers secrete high
amounts of HH ligand to induce tumor-promoting HH target genes
in the adjacent stroma [66–70]. Yet tumor cells themselves were
sometimes found not to be sensitive to HH [68]. Secreted HH
ligands may serve to stimulate the tumoral stroma to maintain a
microenvironment highly suitable for tumor growth [71]. In
particular, HH ligands have been shown to stimulate angiogenesis
[72], immune escape [73], stromal ﬁbroblasts [74], as well as
osteoblasts and osteoclasts whose activation promotes the estab-
lishment and growth of osteolytic metastases from breast cancer
cells [75,76]. Inversely, stromal production of HH ligands promotes
tumor growth and dissemination of solid tumors such as BCC or
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proliferation, resistance to apoptosis, increased genomic instabil-
ity, as well as cell migration and invasiveness, and could also favor
the growth of hematologic malignancies such as B-cell lymphoma
[69].
Experimental models mimicking aberrant HH signaling activa-
tion have demonstrated the importance of this pathway for tumor
initiation and progression. For example, GLI1 and GLI2 overexpres-
sion in keratinocytes of the basal epidermal layer in mice induces
multiple skin tumors exhibiting features characteristic of human
BCC [77–80]. Conversely, GLI2 knockdown reduces colony forma-
tion, anchorage-independent growth in vitro and tumor growth
in vivo of prostatic tumor cells [81].3. HH in cancer: a story of multiple crosstalks
HH signaling may however not be view as a lone effector during
tumorigenesis, as it cooperates with various other oncogenic
events for tumor formation and progression to metastasis. These
include inactivation of tumor suppressors including p53 [82],
NOTCH and PTEN [83,84], activated EGF receptor (EGFR) or onco-
genic KRAS [85,86], as well as the WNT/b-catenin pathway [87],
to cite a few.
Several lines of evidence point for a reciprocal suppressive rela-
tionship between the p53 and HH pathways. p53 negatively regu-
lates both the nuclear localization and the levels of GLI1 in neural
stem and tumor cells [82]. Conversely, activation of the HH path-
way by overexpression of a constitutive active mutant of SMO,
exogenous SHH ligand, or GLI1/GLI2 overexpression, inhibits the
accumulation of p53 protein through phosphorylation and activa-
tion of the p53 inhibitor MDM2 [88]. Finally, cooperation of GLI2
overexpression with p53 deﬁciency has been shown to contribute
to the progression from benign to malignant cartilage tumors in a
mouse model [89].
NOTCH signaling is involved in an array of fundamental pro-
cesses in both embryonic development and adult tissues [90].
Depending on context, NOTCH may serve as a tumor suppressor
or as an oncogenic pathway [91,92]. Remarkably, Notch1 deﬁciency
in murine epidermis results in a sustained expression of GLI2,
which is involved in the development of BCC-like tumors [93].
Cooperation of the IGF/PI3K/AKT pathway with HH signaling on
tumor development has been described in tumor mice models [94].
Targeted expression of SHH and IGF2 to nestin-expressing neural
progenitors in cerebella of newborn mice synergize for medullo-
bastoma formation [94]. Moreover, PI3K/AKT activity is essential
for SHH signaling in the speciﬁcation of neuronal fates in chicken
neural explants and for chondrogenic differentiation of 10T1/2
cells [95]. Mechanistically, it was shown that PI3K/AKT activation
inhibits GLI2 phosphorylation mediated by PKA in NIH3T3 cells,
thus enhancing GLI2-dependent transcription. Inversely, PTEN, a
negative regulator of the PI3K/AKT pathway often mutated in hu-
man cancer, has been shown to negatively regulate transcriptional
activity of GLI1 in glioblastoma cells [84]. Also, Stecca and co-
workers have shown that RAS-MEK and AKT signaling regulate
the nuclear localization and transcriptional activity of GLI1 in mel-
anoma and other cancer cells [96].
Oncogenic KRAS increases the stability of GLI1 protein and pro-
motes its transcriptional activity in pancreatic cancer cells [86,97].
Transgenic mouse models have shown that HH and KRAS cooper-
ate at early stages of pancreatic carcinogenesis [98]. However, pan-
creas cancer cells presenting KRAS mutation are insensitive to HH,
yet they secrete high levels of HH ligand that induces an activation
of stromal cells [68,99].
The HH and EGFR pathways cooperate to stimulate proliferation
of neocortical stem cells [100,101] and invasive growth ofkeratinocytes [102]. Furthermore, integration of HH and EGFR
pathway signals synergistically promotes transformation and can-
cer cell proliferation in vitro and in vivo, via mechanisms that may
or may not involve cooperation of GLI proteins with AP-1 tran-
scription factors [16,103,104].
Several studies have described interactions between the HH and
WNT/b-catenin pathways during dorso-ventral patterning of the
nervous system. SHH through GLI3 controls WNT/b-catenin activa-
tion and conversely WNT/b-catenin controls GLI2 and GLI3 expres-
sion [105,106]. WNT protein expression can also be regulated by
HH pathway [107]. Both pathways cooperate in the myogenic
determination in the somite by inducing MYF5 expression: binding
of both a TCF/b-catenin complex and GLI1 to the enhancer of MYF5
promoter cooperatively activates MYF5 expression [108]. WNT/b-
catenin signaling may also regulate GLI2 and GLI3 activation inde-
pendently on SHH [109]. Various human cancers exhibit a co-
expression or a co-activation of HH and WNT/b-catenin signaling
components, such as in BCC or in pancreatic ductal adenocarci-
noma [110,111]. Also, constitutive activation of HH signaling in
mouse epidermis using a constitutively active mutant form of
SMO initiates tumor formation and induces activation of the
WNT/b-catenin pathway, which is required for HH-driven tumori-
genesis [110]. Activation of the WNT/b-catenin by HH pathway has
also been reported in pancreatic adenocarcinoma cells [111].
Expression of SHH is induced by the oncogenic transcription
factor NF-jB in pancreatic cancer cells [112] and rhabdomyosar-
coma cells [113]. In the latter case, NF-jB binding sites on SHH
promoter have been identiﬁed. Induction of SHH is involved in
NF-jB-induced proliferation and resistance to TRAIL-induced
apoptosis.4. HH-independent GLI activation
A few years ago, GLI proteins were only described as mediators
of HH signaling. However, a growing body of evidence indicates
that GLI expression and activation is regulated by growth factors/
signaling cascades other than HH, and independently from HH.
One of the early evidences for HH ligand-independent GLI func-
tion came from studies in the developing embryo, in which GLI-
dependent transcription was observed in regions devoid of HH li-
gands. GLI expression and activity was, for example, attributed to
FGF signaling during antero-posterior embryonic patterning
[114]. Recently, in a model aimed at understanding the mecha-
nisms of immunoglobulin secretion by malignant cells, it was
found that CCL5/RANTES stimulation of Waldenströmmacroglobu-
linemia bone marrow stromal cells induces a rapid expression of
GLI2 via a CCR/PI3K-AKT/NF-jB mechanism. GLI2, in turn, induces
the expression of IL-6, leading to secretion of IgM by malignant B
cells [115].
In Ewing sarcoma, GLI1 was found to be a direct transcriptional
target of EWS-FLI, the oncogenic transcription factor derived from
chromosomal translocation between chromosomes 11 and 22
[116]. Expression of GLI1 was shown to promote the growth of Ew-
ing Sarcoma tumors [117].
SMO-independent GLI activation by TNF-a was uncovered in
esophageal cancer. Speciﬁcally, it was found that an activated
mTOR/S6K1 pathway downstream of TNF-a promotes GLI1 onco-
genic and transcriptional activities through phosphorylation of
Ser84. This, in turn, releases GLI1 from SUFU and allows for nuclear
translocation in an active form. No changes in total GLI1 levels
were observed [118]. Other signaling pathways capable of inducing
the expression of GLI proteins are the FGF, EGF, MAPK and TGF-b
pathways, whose role in development and cancer progression
may sometimes involve GLI-dependent mechanisms (reviewed in
[11,119]).
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A few years ago, we identiﬁed GLI2, the most transcriptionally
active of GLI proteins, as an early gene target of the TGF-b/SMAD
cascade independent of Hedgehog signaling [120]. The capacity
of TGF-b to rapidly induce GLI2 expression, even in the presence
of cycloheximide, suggested that GLI2 is a direct target of SMADs,
and did not require protein neosynthesis to occur. Subsequent
cloning of the human GLI2 promoter conﬁrmed this hypothesis
and revealed that GLI2 transcription in response to TGF-b is med-
iated by the rapid recruitment of both SMAD3 and b-catenin to dis-
tinct elements of the GLI2 promoter in response to TGF-b [121].
Induction of GLI2 was observed in a variety of human cell types,
both normal and transformed, as well as in cell lines derived from
various cancers including breast and pancreatic carcinoma, glio-
blastoma and cutaneous melanoma [120]. Remarkably, GLI2
expression was found to be dramatically elevated in the epidermis
of K5-TGF-b mice, which exhibit a hyperproliferative phenotype
resembling psoriasis [122]. Both high GLI2 expression and epider-
mal hyperproliferation were lost upon crossing these mice on a
Smad3 deﬁcient background. SMAD3-dependency of GLI2 expres-
sion downstream of TGF-b signaling was veriﬁed in vitro by means
of SMAD3 siRNA knockdown [120].
Interestingly, GLI1, whose expression is often considered a spe-
ciﬁc marker of HH pathway activation in a plethora of publica-
tions, is induced by TGF-b in a GLI2-dependent manner, and
such induction by TGF-b is not sensitive to cyclopamine, a SMO
antagonist, demonstrating a lack of requirement for HH signaling.
In a study comparing the ability of cyclopamine (a HH inhibitor
that blocks SMO-dependent GLI1 expression) to inhibit the
growth of, and induce apoptosis of, pancreatic cancer cells in
vitro, Hebrok and co-workers found that despite similarly ele-
vated GLI1 levels, only about 50% of cell lines tested were sensi-
tive to the drug [123]. Remarkably, we found that basal GLI2
and GLI1 expression in these cyclopamine-resistant cell lines, as
well as their proliferative capacity, were greatly inhibited by an
ALK5 small molecule inhibitor and by transfected GLI2 siRNA
oligonucleotides, while unaltered by cyclopamine [120]. These
experiments thus demonstrated that autocrine TGF-b signaling,
not HH activity, was responsible for high GLI expression and
resulting high proliferative capacity of these cyclopamine-resis-
tant pancreatic carcinoma cell lines.6. The TGF-b/GLI2 couple in cancer
During the course of our investigations, we compared GLI2
expression in a series of human melanoma cell lines, in which con-
stitutive TGF-b/SMAD signaling was previously characterized. We
found that basal GLI2 expression in melanoma cells largely de-
pends upon autocrine TGF-b signaling and that high GLI2 expres-
sion is associated with loss of E-cadherin expression and
increased invasive capacities [124,125]. Loss of E-cadherin in mel-
anoma is associated with the switch from radial to vertical growth
phase of the primary tumor, leading to invasion of the dermis and
further dissemination and metastasis. In epithelial cells, loss of E-
cadherin is one of the key molecular events that takes place during
the so-called epithelial to mesenchymal transition (EMT) a com-
plex phenotypic conversion that involves changes in morphology,
differentiation and cell–cell adhesion, and acquisition of a motile
behavior together with other mesenchymal traits. EMT is observed
at various stages of embryonic development where intense tissue
remodeling takes place and also represents a critical mechanism
by which pre-malignant epithelial cells acquire a highly invasive
phenotype that leads to metastatic spreading [126]. An EMT signa-
ture is usually associated with poor prognosis in various cancers[127]. Remarkably, the link between EMT and GLI-dependent gene
regulation was previously established [128], and TGF-b is a
prototypic cytokine capable inducing this phenotypic switch
[129], suggesting that GLI-dependent mechanisms may take place
downstream of TGF-b in the context of EMT.
GLI1 was shown previously to induce an EMT in rat kidney epi-
thelial cells via induction of the E-cadherin repressor SNAIL [128].
In melanoma, we found that high GLI2 expression is associated not
only with loss of E-cadherin, but also with increased cell invasive-
ness in vitro and capacity to form bone metastases in mice [124].
Mechanistically, we found that GLI2 knockdown in highly invasive
melanoma cells, i.e. strongly expressing GLI2, dramatically reduced
their capacity to invade Matrigel and to form bone metastases in
nude mice, thus providing direct evidence for a driving role of
GLI2 in melanoma cell invasion, and for the relevance of GLI2 tar-
geting to treat melanoma skeletal metastases. Remarkably, the efﬁ-
cacy of targeting TGF-b signaling to interfere with bone metastasis
in the same mouse model was previously established [130–132].
We identiﬁed PTHrP, IL-11, CXCR4 and OPN as TGF-b-regulated
genes, whose expression was greatly reduced by both SMAD7 over-
expression [131] and by systemic administration of the TbRI inhib-
itor SD-208 [130]. These pro-metastatic genes are also critical for
TGF-b-dependent establishment of bone metastases by MDA-MB-
231 breast carcinoma cells in the same mouse model [133,134].
Remarkably, overexpression of a dominant-negative form of GLI2
targeting in the latter cells was shown to inhibit the establishment
and growth of bone metastases [135]. The authors conﬁrmed our
initial observations that GLI2 expression in MDA-MB-231 cells is
induced by TGF-b [120]. In both cases, the anti-metastatic potential
of GLI2 or TGF-b targeting was linked to inhibition of critical target
genes including the osteoclastogenic factor PTHrP. Noteworthy,
GLI1 has been shown to regulate OPN expression in melanoma
and breast cancer cells, promoting malignant behavior, osteo-
clastogenesis, and subsequent osteolysis [18,75]. A schematic of
TGF-b/HH interactions is provided in Fig. 2.
In a mouse model of breast cancer progression from ductal
carcinoma in situ (DCIS) to invasive carcinoma, others have found
that TGF-b1 is responsible for both increased GLI2 expression and
GLI-dependent transcription in MCFDCIS cells [136]. This deriva-
tive of MCF10A breast carcinoma cells forms, upon implantation
in mice, DCIS comedo-like tumors that spontaneously progress to
invasive tumors [137]. In their study, the authors found that
TGF-b-dependent GLI2 expression and GLI-dependent transcrip-
tion, had a positive effect on myoepithelial cell differentiation
and progression to invasion. In another study targeting BMP recep-
tors speciﬁcally in the ovary, Bmpr1a Bmpr1b double-mutant mice
developed granulosa cell tumors with enhanced constitutive TGF-b
signaling associated with elevated GLI2 (and GLI1) expression
[138]. GLI2 was subsequently identiﬁed as a TGF-b regulated gene
in normal granulosa cells. Also, it was recently found that ovarian
cancer stem cells in recurrent tumors overexpress GLI1 and GLI2
together with effectors of the TGF-b pathway including the
co-receptor endoglin, as compared to the primary tumors [139].
The authors found that knockdown of reduced tumor cell viability
and resistance to cisplatin.
In a series of bladder cancer cell lines, it was found that
HH-independent GLI2 expression and function contributes to inva-
siveness. The authors suggested that non-canonical GLI2 activity
may be attributed to RAS and TGF-b, both of these pathways being
critical for bladder cancer development [140].7. A HH–TGF-b ampliﬁcation loop in cancer?
A number of situations display crosstalks between the TGF-b and
HH pathways. For example, in gastric cancer cells, HH signaling
Fig. 2. TGF-b and HH signaling crosstalks. TGF-b ligands induce cellular responses through membrane-bound, heteromeric serine/threonine kinase receptor complexes,
which phosphorylate and activate SMAD proteins, whose subsequent accumulation in the nucleus allows target gene transactivation. SMAD3/SMAD4 complexes, in
cooperation with b-catenin, induces GLI2 expression [121]. The TGF-b pathway may contribute to GLI-speciﬁc responses by at least two mechanisms: TGF-b-induced GLI2
may participate in the signal transduction activated by HH ligand and reinforce HH-inducible transcriptional response. TGF-b may inhibit PKA activity, thus limiting GLI
protein processing by the proteasome. TGF-b-induced GLI2 may also act independently on HH pathway and directly activate its transcriptional targets. GLI2-induced genes
participate in EMT, tumor and bone metastasis development. The TGF-b and HH pathways may thus cooperate to promote cancer disease progression.
D. Javelaud et al. / FEBS Letters 586 (2012) 2016–2025 2021induces the expression of TGF-b family members, and the latter are
likely to be involved in SMO-dependent tumorigenesis, as
Shh-induced cell motility and invasiveness requires TGF-b-driven
activation of the SMAD pathway [141]. Also, expression of a consti-
tutively active form of SMO under the control of the K14 promoter
leads to the development of BCC in mice, accompanied with induc-
tion of TGF-b2 expression and activation of the TGF-b signaling
pathway. A small molecule TbRI inhibitor prevented tumor devel-
opment, associated with increased lymphocyte inﬁltrates, suggest-
ing that TGF-b is critical for SMO-mediated cancer development
through its immunosuppressive activity [142].
While TGF-b likely contributes to some of HH biological effects,
it is also highly likely that the opposite is true, as TGF-b-driven
EMT in non-small cell lung cancer cells was shown to be inhibited
by pharmacologic inhibitors of the HH pathway. The authors
showed that TGF-b induced SHH expression in these cells, which
in turn activated GLI1 and GLI1-dependent EMT [143]. Inversely,
we recently showed that TGF-b inhibits PKA activity while con-
comitantly inducing GLI2 and GLI1 expression [144]. PKA blockade
may contribute to increase the pool of full-length activator GLI
proteins in the cell, thus allowing a possible HH response. Takentogether, these reports indicate that TGF-b and HH signaling may
form a vicious cycle promoting and amplifying the metastatic pro-
cess whereby GLI2, and its downstream target GLI1, play a major
role in allowing promoting tumor cell invasion and resistance to
apoptosis.
Noteworthy, neuropilins may represent a critical node linking
HH and TGF-b signaling in cancer and ﬁbrosis. Neuropilin-1
(NRP1) has recently been shown to function as a co-receptor for
TGF-b on the membrane of cancer cells, and to enhance the
canonical SMAD2/3 signaling in response to both latent and ac-
tive TGF-b [145]. This activity of NRP1 is not limited to cancer
cells as it also enhances TGF-b-dependent regulatory T cell activ-
ity [146] and promotes liver cirrhosis and associated vascular
changes by enhancing PDGF and TGF-b signaling in hepatic stel-
late cells [147]. At the mean time, NRPs have been shown to pos-
itively regulate HH signaling, mediating HH transduction between
activated SMO and SUFU, resulting in increased maximal HH
target gene activation [148]. Furthermore, as NRP1 transcription
itself is augmented by HH signaling [149], it suggests the exis-
tence of a feed-forward mechanism of HH signal ampliﬁcation
via NRP.
2022 D. Javelaud et al. / FEBS Letters 586 (2012) 2016–20258. Is tissue ﬁbrosis a HH disease?
Remarkably, a few recent reports now implicate HH signaling
in the development of tissue ﬁbrosis affecting various organs,
including skin, lung and liver. For example, it has been shown that
the small molecule inhibitor of HH signaling LDE223 and SMO
siRNAs inhibit bleomycin-induced dermal ﬁbrosis and exerts
anti-ﬁbrotic activities in tight-skin-1 mice [150]. Not only did
these approaches prevent progression of ﬁbrosis, they also
induced regression of pre-established disease. In non-alcoholic
hepatic ﬁbrosis, it has been shown that HH pathway activation
parallels the severity of tissue injury [151], as estimated by the
number of SHH and GLI2 positive cells that was found to increase
with disease stage, as well as expression of HH target genes. HH
antagonists were shown to promote the regression of both liver
ﬁbrosis and hepatocellular carcinoma in mice [152]. Similarly, a
role for HH signaling in the pathogenesis of renal ﬁbrosis was
recently described [153,154].
Fibrosis has long been considered a prototypic pathological con-
dition of TGF-b-driven disease, mainly through its capacity to act
on extracellular matrix deposition and remodeling [155–158].
GLI2 is directly and transcriptionally induced by the TGF-b path-
way in a wide variety of cell types and in various physio-patholog-
ical situations [120,136–138]. Since GLI2 is the prime substrate for
HH signaling [4], it becomes highly likely that TGF-bwill be able to
induce HH responsiveness to cells that did not express GLI2 prior
to TGF-b exposure. Interestingly, simultaneous expression of
TGF-b1 and SHH was detected by immunohistochemistry in epi-
thelial cells from both human lung ﬁbrosis (cryptogenic ﬁbrosing
alveolitis and bronchiectasis), and allergen-induced lung ﬁbrosis
in mice [159]. It cannot be excluded that TGF-b may contribute
to the expression of GLI2 in injured tissue where it may serve as
a substrate for strengthen HH signals in a self-amplifying patho-
genic loop.9. Concluding remarks
Targeting the HH pathway for cancer treatment by means of
SMO antagonists has shown remarkable efﬁcacy in the pre-clinical
and clinical settings, against tumors (basal cell carcinoma (BCC) of
the skin, pancreatic carcinoma) with identiﬁed mutations in the
upstream components of the pathway [160]. Yet, a number of tu-
mors exhibiting high expression of GLI1 are oblivious to HH signal-
ing inhibition, suggesting the existence of alternate pathways
leading to expression of downstream HHmediators. We and others
have contributed to identify TGF-b as a potent transcriptional reg-
ulator of GLI2, resulting in GLI1 activation independently from the
HH signaling cascade. In addition to facilitating direct GLI2-depen-
dent oncogenic events, it is plausible that TGF-b (and other signals
capable of inducing GLI2 expression) may prime or potentiate HH
responsiveness by elevating the available pool of GLI2, a critical
component of the HH response.
The vast majority of publications describing the roles of TGF-b
or HH signaling in cancer (and ﬁbrosis) examined these cytokines
independently from each other. It will now be important to simul-
taneously evaluate the respective contribution of both pathways in
disease to characterize the proper target(s) for therapeutic inter-
vention at a given stage of disease progression.Acknowledgements
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